Healios K.K. (4593.T)
JPY 181.0
(1.69%)
JPY 181.0
(1.69%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.15 Billion JPY | 0.81% |
| 2022 | 15.03 Billion JPY | -37.29% |
| 2021 | 23.97 Billion JPY | 3.45% |
| 2020 | 23.17 Billion JPY | 9.8% |
| 2019 | 21.1 Billion JPY | 40.87% |
| 2018 | 14.98 Billion JPY | -23.95% |
| 2017 | 19.69 Billion JPY | 114.68% |
| 2016 | 9.17 Billion JPY | -12.52% |
| 2015 | 10.48 Billion JPY | 230.65% |
| 2014 | 3.17 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 16.48 Billion JPY | 8.77% |
| 2024 Q2 | 17.81 Billion JPY | 8.05% |
| 2023 Q2 | 14.69 Billion JPY | -3.29% |
| 2023 Q4 | 15.15 Billion JPY | -15.66% |
| 2023 FY | 15.15 Billion JPY | 0.81% |
| 2023 Q3 | 17.97 Billion JPY | 22.32% |
| 2023 Q1 | 15.19 Billion JPY | 1.04% |
| 2022 Q3 | 14.91 Billion JPY | -28.14% |
| 2022 Q2 | 20.76 Billion JPY | -7.71% |
| 2022 Q1 | 22.49 Billion JPY | -6.15% |
| 2022 FY | 15.03 Billion JPY | -37.29% |
| 2022 Q4 | 15.03 Billion JPY | 0.76% |
| 2021 Q1 | 22.17 Billion JPY | -4.31% |
| 2021 FY | 23.97 Billion JPY | 3.45% |
| 2021 Q4 | 23.97 Billion JPY | -8.02% |
| 2021 Q2 | 20.2 Billion JPY | -8.88% |
| 2021 Q3 | 26.06 Billion JPY | 29.0% |
| 2020 Q1 | 28.53 Billion JPY | 35.23% |
| 2020 Q2 | 26.39 Billion JPY | -7.51% |
| 2020 Q3 | 24.07 Billion JPY | -8.79% |
| 2020 Q4 | 23.17 Billion JPY | -3.75% |
| 2020 FY | 23.17 Billion JPY | 9.8% |
| 2019 Q3 | 22.44 Billion JPY | 80.24% |
| 2019 FY | 21.1 Billion JPY | 40.87% |
| 2019 Q2 | 12.45 Billion JPY | -8.17% |
| 2019 Q1 | 13.55 Billion JPY | -9.49% |
| 2019 Q4 | 21.1 Billion JPY | -5.97% |
| 2018 FY | 14.98 Billion JPY | -23.95% |
| 2018 Q2 | 18.44 Billion JPY | -1.99% |
| 2018 Q4 | 14.98 Billion JPY | -14.56% |
| 2018 Q1 | 18.82 Billion JPY | -4.43% |
| 2018 Q3 | 17.53 Billion JPY | -4.97% |
| 2017 Q2 | 16.73 Billion JPY | 58.4% |
| 2017 Q3 | 17.02 Billion JPY | 1.73% |
| 2017 Q1 | 10.56 Billion JPY | 15.14% |
| 2017 Q4 | 19.69 Billion JPY | 15.7% |
| 2017 FY | 19.69 Billion JPY | 114.68% |
| 2016 FY | 9.17 Billion JPY | -12.52% |
| 2016 Q2 | 10.39 Billion JPY | -2.46% |
| 2016 Q1 | 10.65 Billion JPY | 1.62% |
| 2016 Q4 | 9.17 Billion JPY | -6.41% |
| 2016 Q3 | 9.8 Billion JPY | -5.69% |
| 2015 Q4 | 10.48 Billion JPY | -2.89% |
| 2015 Q2 | 10.08 Billion JPY | 0.0% |
| 2015 FY | 10.48 Billion JPY | 230.65% |
| 2015 Q3 | 10.79 Billion JPY | 7.11% |
| 2014 FY | 3.17 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -129.993% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -1151.005% |
| GNI Group Ltd. | 62.39 Billion JPY | 75.711% |
| Linical Co., Ltd. | 18.53 Billion JPY | 18.257% |
| Trans Genic Inc. | 9.81 Billion JPY | -54.469% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -168.985% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -118.179% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -160.559% |
| AnGes, Inc. | 28.89 Billion JPY | 47.547% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -1647.427% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 90.359% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -836.313% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -198.84% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -248.4% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -522.931% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -538.543% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -118.678% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -765.281% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -198.001% |
| PeptiDream Inc. | 67.12 Billion JPY | 77.423% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -642.674% |
| Ribomic Inc. | 3.54 Billion JPY | -327.232% |
| SanBio Company Limited | 5.04 Billion JPY | -200.26% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -1131.856% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -402.487% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -928.047% |
| StemRIM | 9.08 Billion JPY | -66.905% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -120.285% |
| FunPep Company Limited | 2.49 Billion JPY | -508.357% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -478.732% |
| Stella Pharma Corporation | 3.82 Billion JPY | -296.663% |
| TMS Co., Ltd. | 3.55 Billion JPY | -326.33% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -162.245% |
| Cuorips Inc. | 6.18 Billion JPY | -145.039% |
| K Pharma,Inc. | 3.31 Billion JPY | -357.316% |
| Takara Bio Inc. | 123.2 Billion JPY | 87.7% |
| ReproCELL Incorporated | 9.05 Billion JPY | -67.41% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -458.129% |
| StemCell Institute Inc. | 6.54 Billion JPY | -131.619% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -116.848% |
| CellSeed Inc. | 2.46 Billion JPY | -514.616% |